Self-GRAS vs FDA-Notified GRAS for Ingredient Manufacturers: Dossier, Expert Panel and Regulatory Posture

GRAS is not a lower bar than food additive approval; the safety standard is identical — 'reasonable certainty of no harm' under intended conditions of use. The difference is the evidentiary route: GRAS requires that the safety conclusion be 'generally recognized' by qualified experts based on publicly available scientific data and information, whereas food additive approval can rely on confidential proprietary data submitted to the FDA. 21 CFR 170.30 sets two pillars: (1) the scientific data demonstrating safety must be of the same quantity and quality as would support a food additive petition, and (2) those data must be generally available and accepted in the relevant scientific community. A safety conclusion drawn from unpublished proprietary toxicology studies is not GRAS — it is a food additive determination wearing the wrong hat. The intended use is part of the conclusion: GRAS is GRAS for a specified ingredient, at specified levels, in specified food categories, for a specified consumer population.

A defensible GRAS conclusion is reached by an expert panel that is qualified by training and experience to evaluate the safety of the ingredient at issue. FDA expects: (1) panel members with credentials in the relevant disciplines — typically toxicology, pharmacology, food science, nutrition, biochemistry, and where relevant, microbiology or pharmacognosy; (2) independence from the sponsor — panellists should not be employees of the sponsor, and conflicts should be disclosed and managed; (3) a formal panel review of the dossier; (4) a signed Expert Panel Statement concluding GRAS under the specified conditions of use. The FDA's 2016 final rule (21 CFR 170 Subpart E) reaffirmed that GRAS conclusions reached by a single individual rather than a panel are unlikely to meet the 'general recognition' standard. The Expert Panel Statement is the linchpin document — without it, neither self-GRAS nor notified GRAS is defensible.

Self-GRAS: the dossier and expert panel statement are prepared and held in the company's files. The ingredient may be marketed immediately. Advantages: speed, confidentiality, no FDA queue. Disadvantages: no FDA acknowledgement, customer due diligence may demand a notification, and the company carries full enforcement risk if the FDA disagrees with the conclusion. FDA-notified GRAS: the same dossier is submitted to the FDA Office of Food Additive Safety under the GRAS Notification Program, the FDA issues a GRN number and (typically within 180 days) either a 'no questions' letter, a 'cease to evaluate' letter on sponsor request, or insufficient-basis correspondence. Advantages: third-party validation, GRN number visible on the FDA website, far smoother customer and retailer onboarding. Disadvantages: timeline, dossier becomes substantially public, FDA may push back on intended-use scope. Most ingredient manufacturers selling to mainstream food and beverage customers pursue notified GRAS; smaller suppliers selling primarily into supplements often run self-GRAS first and notify later when customer pressure requires.

A GRAS dossier follows a stable structure regardless of self-determination vs notification. (1) Common or usual name and trade names. (2) Ingredient identity — composition, manufacturing process, specifications, analytical methods, batch-to-batch consistency data. (3) Intended use — food categories, use levels, technical effect, total estimated daily intake. (4) Self-limiting levels of use where applicable (e.g. organoleptic limits). (5) Safety narrative — mode of action, ADME, sub-chronic and chronic toxicology, genotoxicity, reproductive and developmental toxicity, allergenicity, human exposure data, history of consumption where relevant. (6) Comparable regulatory status in other jurisdictions (EFSA, FSANZ, Health Canada). (7) Expert Panel Statement and member CVs. (8) References — all studies cited must be publicly available; proprietary studies may be summarised but cannot be the sole basis. (9) For notifications: the formal GRAS notification template per 21 CFR 170 Subpart E. Common deficiencies: under-specified intended use, missing analytical specifications, inadequate exposure assessment, panel members with undisclosed sponsor relationships.

GRAS and NDI are not interchangeable. DSHEA defines a dietary supplement as containing a dietary ingredient — vitamin, mineral, amino acid, herb or botanical, dietary substance for use to supplement the diet, or concentrate/metabolite/constituent/extract of these. An ingredient marketed in the US as a dietary ingredient before 15 October 1994 is grandfathered; anything newer triggers the New Dietary Ingredient notification pathway, requiring submission to the FDA 75 days before marketing with evidence of reasonable expectation of safety. GRAS status as a food additive does NOT automatically authorise use as a dietary ingredient (or vice versa), and the FDA has issued enforcement letters where a notified-GRAS food ingredient was marketed as a supplement ingredient without an NDI notification. Practical rule for supplement brand-owners: an ingredient sold for supplement use needs either pre-DSHEA status, an accepted NDI notification, or qualification under one of the narrow exemptions — GRAS alone is not sufficient. An ingredient sold for dual food and supplement use typically needs both a GRAS conclusion (for food use) and an NDI notification (for supplement use).